Form 4: Greenwich LifeSciences Director Eric Rothe Acquires Stock Options
SEC Form 4
Director Eric Rothe of Greenwich LifeSciences, Inc. acquired 41,349 stock options on December 24, 2024, increasing his total holdings to 82,698.
Summary
- Eric Rothe, a director at Greenwich LifeSciences, Inc., acquired 41,349 stock options on December 24, 2024.
- These options have an exercise price of $12.16.
- The options vest over a period of 36 months, with 10,337 vesting immediately and the remainder vesting monthly.
- Following this transaction, Mr. Rothe's total holdings of stock options in the company increased to 82,698.
- The options expire on December 24, 2034.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of stock option grants, which is neither particularly positive nor negative. It indicates that a director is incentivized to perform well for the company.
Positives
- The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future.
Industry Context
This is a standard SEC Form 4 filing, which is common for company insiders who have transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.
Comparison to Industry Standards
- Stock option grants to directors are a common practice in publicly traded companies as a form of compensation and incentive.
- The vesting schedule of 36 months is also a typical arrangement to align the director's interests with the long-term performance of the company.
- The specific terms of the options, such as the exercise price and expiration date, are specific to Greenwich LifeSciences and would need to be compared to similar grants at comparable companies to assess their relative value.
Stakeholder Impact
- The acquisition of stock options by a director may be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 12/24/2024 | Date of stock option acquisition. |
| 12/27/2024 | Date of filing the Form 4. |
| 12/24/2034 | Expiration date of the stock options. |
Keywords
stock options, insider trading, beneficial ownership, Greenwich LifeSciences, GLSI, director, Eric Rothe
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.